New Data Highlight Early Intervention with the UroLift® System Facilitates Long-Term Positive Outcomes for BPH Patients2-4

Matt Ashley, MD
Associate Medical Director
Teleflex Interventional Urology

It was nice to see so many of our peers coming together for a successful AUA Annual Meeting in Chicago. Our team was once again excited to see new research findings reinforcing the long-term durability of Prostatic Urethral Lift (PUL) with the UroLift®System, as well as lower complication rates compared to other minimally invasive procedures for men with benign prostatic hyperplasia (BPH)2-4. These results help reinforce why the UroLift® System is the number one minimally invasive BPH procedure chosen by urologists and their patients in the U.S.1 Please click here to find the press release recently issued by Teleflex.

Several new analyses highlighted some of the unique benefits of the UroLift® System. Key findings from the studies are: 

We continue to see evidence that early treatment prior to severe symptoms positively impacts long-term durability.2 An analysis of more than 330 subjects treated in a controlled setting showed the UroLift® System was durable in most subjects at one and five years. In this analysis, 13.7% of subjects needed surgical retreatment at five years, consistent with the five-year retreatment rate reported in the L.I.F.T. study (13.6%). The research also showed that earlier treatment in the disease continuum, indicated by factors such as better overall International Prostate Symptom Score (IPSS) and quality of life (QoL) scores at baseline, was associated with long-term durability.

The largest healthcare utilization study for BPH therapies in the US continues to show the UroLift® System has the lowest complication rate and that medical therapy is not without consequences.3 The analysis consisted of data on more than 200,000 men with BPH treated with medical therapy, minimally invasive surgical treatment, or invasive surgery. Among patients undergoing minimally invasive or more invasive surgical treatments, procedure complication rates were lowest for the UroLift® System (17%) and highest for Rezūm™ (28%), and rates were similar between TURP, PVP and Aquablation® (~22%, 21% and 20% respectively).3 The analysis also showed that approximately 6% of medical therapy patients underwent BPH-related interventions (including cystoscopy, catheterization, and bladder irrigation) in the next year as the disease progressed. 

Earlier intervention in patients with urinary retention increases the likelihood of becoming catheter-independent after treatment.4 Results from the UK-based PULSAR (Prostatic Urethral Lift in Subjects With Acute Urinary Retention) study (n=51) were compared to 388 patients in urinary retention in the real-world retrospective study. After treatment with the UroLift® System, 73% of PULSAR study subjects and 80% of real-world study subjects were catheter-free with no additional surgeries at 12 months; success was associated with higher voiding efficiency during the perioperative period. Variables that influenced success included age (<70 years) at procedure, lower baseline prostate-specific antigen (PSA) and post-void residual (PVR) levels, and shorter pre-procedural catheter duration. These data may help providers to better understand results after the UroLift® System procedure and enable more men in urinary retention to obtain safe and effective BPH treatment.

These new and meaningful analyses continue to highlight the benefit of early intervention in facilitating long-term durability outcomes.

It’s time we change our patients’ journeys with confidence. 

References

1. U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22 FINAL), which is in part based on Symphony Health PatientSource® 2018-21, as is and with no representations/warranties, including accuracy or completeness.

2. Roehrborn, et al, AUA 2023. Durability following treatment with the Prostatic Urethral Lift (PUL): Predictors from over 330 controlled subjects across 5 distinct studies. [Conference Presentation] Study sponsored by Teleflex Incorporated or its affiliates.

3. Kaplan, et al, EAU 2023. The Impact of BPH Care: Procedural Complications Associated with MIST and Traditional Surgery Compared to Disease Progression with Medical Therapy. [Conference Presentation] Study sponsored by Teleflex Incorporated or its affiliates.

4. Kayes, et al, AUA 2023. Successful Outcomes in Acute Urinary Retention (AUR) Patients Treated with the Prostatic Urethral Lift (PUL) are Associated with Earlier Intervention. [Conference Presentation] Study sponsored by Teleflex Incorporated or its affiliates.

5. Roehrborn, J Urology 2013. 

 

MAC02695-01 Rev A